초록

It has been found that a novel antibiotic can be obtained by the fermentation of certain strains of Streptomyces olivaceus and related organisms. In addition to being a potent antibiotic this new material which we have designated MM 13902 acts synergistically with penicillins and cephalosporins.

대표청구항 ▼

A process for the preparation of a pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C13H16O8N2S2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueou

A process for the preparation of a pharmaceutically acceptable di-basic salt of MM 13902 which is at least 50% pure wherein MM 13902 is a solid carboxylic acid of the molecular formula C13H16O8N2S2 which in the form of a substantially pure sodium salt has the following characteristics: (a) in aqueous solution, it has a characteristic ultra-violet spectrum with absorption maxima at about 305 nm and at about 225 nm substantially as shown in FIG. 1; (b) when present at 0.4% w/w in a freshly prepared KBr disc, it has a characteristic infra-red spectrum which has absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260 cm-1; (c) it has a characteristic N.M.R. spectrum when taken in D2O which spectrum possesses inter alia (i) a pair of low field doublets centered at approximately 2.85rand 4.00rwith coupling constants of approximately 14 Hz; (ii) a doublet centered at approximately 8.55rand (iii) a sharp singlet at approximately 8.00r (d) it possesses antibacterial activity against various species including inter alia, strains of Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Salmonella typhi and Pseudomonas aeruginosa; and (e) when mixed with ampicillin it synergizes its activity against organisms including strains of Escherichia coli, Klebsiella aerogenes, Proteus mirabilis, Proteus morganii and Staphylococcus aureus Russell, which comprises chromatographically separating from a solution of MM 4550 (Complex) which contains MM 13902 and impurities a fraction consisting essentially of a solution of a pharmaceutically acceptable di-basic salt of MM 13902 and thereby obtaining a pharmaceutically acceptable di-basic salt of MM 13902 of at least 50% purity.